Galapagos NV announced that GSK provided Galapagos with the following information:
"Study JAK116679 was a phase 2a multi-centre, randomised, double-blind, placebo-controlled, dose ranging study (100mg bid, 200mg bid, 400mg bid) that evaluated the safety and efficacy of GSK2586184 compared with placebo in 66 patients with chronic plaque psoriasis. Preliminary results showed that a significantly higher proportion of patients treated with GSK2586184 at the 400mg bid dose met the primary endpoint compared to placebo.
Good Friday, April 18th, "de Stal" will be closed.
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, has announced new clinical data on its lead product candidate ISA101. ISA101 is a therapeutic cancer vaccine for the treatment of high-risk, HPV16-induced diseases, such as cervical cancer. The data were presented by principal investigator Prof. Sjoerd van der Burg, Ph.D., at this year’s American Association for Cancer Research (AACR) Annual Meeting in San Diego.
New Venture Holland HealthTech and branche organisation FME-CWE together offer € 5000.- cash for the best MedTech idea*. So write your business plan and enter the competition. Deadline is 23 April 2014. The winner will be announced at 26 June in Amsterdam during the New Venture event.
> Read more in Dutch
Welch Allyn celebrates successful opening of its Regional Headquarters and Operations Center in the NetherlandsPublished : Tuesday, April 8, 2014
Leiden, Tuesday 8 April 2014 – Welch Allyn executives, employees and local government officials attended a festive gathering this afternoon to celebrate the successful opening of the company’s Regional Headquarters in Leiden and Operations Center in Tilburg. Speeches for Welch Allyn were given by Steve Meyer (President & CEO), Jon Soderberg (Executive VP & Chief Corporate Development Officer) and Hisham Hout (Executive VP Europe, Middle East & India Sub Continent). Additionally, Dutch Secretary-General for Economic Affairs, Maarten Camps, spoke on behalf of the Dutch government.
Leading Dutch technology institutes CTMM (Center for Translational Molecular Medicine) and TI Pharma have joined forces, in a merger that addresses the growing interdependence of medicines and medical technology.
Impressive joint track records in medical innovation mean that the new combined organization is well placed to achieve both improved healthcare results and wider economic benefits. As a larger player, it will be able to operate more effectively at both a national and a European level.
The oncology team of Janssen Biologics introduced an educational high school outreach program for high school students 4 years ago. The goal of the program is to give high school students more insight in the field of oncology (both pharmaceutical and healthcare) and is a connection between the world of school and the world of work. Based on the success two additional programs (Neuroscience and Ageing) were initiated in close collaboration with Technolab. The program may inspire community giving of other companies in Leiden Bio Science Park and may raise interest in Life Sciences.
> Read more in Dutch
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, announced that principal investigator Prof. Sjoerd van der Burg, Ph.D., will present new clinical data on ISA101 at this year’s American Association for Cancer Research (AACR) Annual Meeting. ISA101 is a therapeutic cancer vaccine for the treatment of high-risk, HPV16-induced diseases.
Are you an employee, entrepreneur, volunteer, student, or job seeker living outside your country of origin? Please fill out this surveyPublished : Monday, March 24, 2014
Our organization is part of the International Community Platform – a platform consisting of the 30 largest international employers of The Hague – Rotterdam Metropolitan region. In 2013, ICP surveyed over 1000 international workers, job seekers, students, entrepreneurs and volunteers in NL. They rated their professional life with an (meager) average score of 6,4. This figure and the increasing relevance of the ‘access to talent’ and ‘dual career’ topics have made the employers of ICP decide to further investigate, in NL and abroad.
Galapagos NV announced that the market of reference will change from Euronext Brussels to Euronext Amsterdam, effective as of 28 March 2014. The change of market of reference means that orders in Galapagos' securities will be gathered and centrally administered in the single order book in Euronext Amsterdam.
The former Anatomy Building of Leiden University will, after renovation, provide housing for PhD students. In the summer of 2015 the new complex will be completed. On March 17 a sheet pile was symbolically drilled into the ground by Willem te Beest, Vice-President of the Leiden University and Leiden city aldermen Pieter van Woensel and Robert Strijk.
> Read more in Dutch
Minister of Education Jet Bussemaker, Loek Dijkman of the UTOPA foundation, the LiS foundation, Henri Lenferink mayor of the city of Leiden, Willem te Beest vice-president of Leiden University and business representatives signed the covenant 'Growth LiS' for enlargement of the successful Leiden instrumentmakers School.
> Read more in Dutch
Prosensa announces 48-week data from a U.S. Phase II placebo-controlled study of Drisapersen in 51 DMD boysPublished : Tuesday, March 18, 2014
Prosensa Holding N.V., the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, reported encouraging 48-week data from its U.S.-based, Phase II placebo-controlled study (DMD114876 or DEMAND V) of its lead compound, drisapersen, for the treatment of Duchenne Muscular Dystrophy (DMD).
Galapagos to present favorable pre-clinical data on GLPG1790, a selective ephrin receptor kinase inhibitor, at AACR in San DiegoPublished : Tuesday, March 18, 2014
Galapagos NV will present favorable pre-clinical data on GLPG1790 in triple-negative breast cancer at the American Association for Cancer Research (AACR) Annual Meeting in San Diego on 7 April 2014. In the abstract, Galapagos disclosed that GLPG1790 is the first selective small molecule inhibitor of the ephrin receptor kinase family, which could play a key role in melanoma, pancreatic, ovarian, prostatic, and colorectal cancers, in addition to triple-negative breast cancer.
Charles River Laboratories to acquire Galapagos' Argenta and BioFocus service operations for up to €134 millionPublished : Thursday, March 13, 2014
Galapagos NV announces the signing of a definitive agreement to sell the BioFocus and Argenta service division operations to Charles River Laboratories International, Inc. (NYSE: CRL) for a total consideration of up to €134 million. The transaction is subject to customary closing conditions and is expected to close early in the second quarter of 2014.
The Leiden Bio Science Park newsletter is a free bimonthly email newsletter in English. The newsletter offers general life science news, news from the companies and institutions, a company profile, events and jobs.
click here to subscribe